Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
New findings in HIV/AIDS described from Drexel University
November 26th, 2008
According to a study from the United States, "The current goal of human immunodeficiency virus type 1 (HIV-1) therapy is to maximally suppress viral replication. Securing this goal requires new drugs and treatment classes." "The chemokine receptor CCR5 provides an entry portal for HIV-1, and PRO 140 is a humanized monoclonal antibody that binds to CCR5 and potently inhibits CCR5-tropic (R5) HIV-1 in vitro. A randomized, double-blind, placebo-controlled, dose-escalating study was conducted in 39 individuals with HIV-1 RNA levels >= 5000 copies/mL, CD4(+) cell counts >= 250 cells/mu L, no antiretroviral therapy for 3 months, and only R5 HIV-1 detectable. Cohorts...
Source: Immunotherapy Weekly (2008-11-26)
|
